Multidisciplinary Effort to Drive Precision-Medicine for the Future

Dewei Kong, Haojie Yu, Xueling Sim, Kevin White, E. Shyong Tai, Markus Wenk and Adrian Kee Keong Teo

In the past one or two decades, countries across the world have successively implemented different precision medicine (PM) programs, and also cooperated to implement international PM programs. We are now in the era of PM. Singapore’s National Precision Medicine (NPM) program, initiated in 2017, is now entering its second phase to generate a large genomic database for Asians. The National University of Singapore (NUS) also launched its own PM translational research program (TRP) in 2021, aimed at consolidating multidisciplinary expertise within the Yong Loo Lin School of Medicine to develop collaborative projects that can help to identify and validate novel therapeutic targets for the realization of PM. To achieve this, appropriate data collection, data processing, and results interpretation must be taken into consideration. There may be some difficulties during these processes, but with the improvement of relevant rules and the continuous development of omics-based technologies, we will be able to solve these problems, eventually achieving precise prediction, diagnosis, treatment, or even prevention of diseases.

Keywords: precision medicine, big data, omics technologies, data collection, data processing, results interpretation, metabolic disease, healthcare

INTRODUCTION

Precision medicine (PM) refers to the medical model that considers individual gene variability, environment, and lifestyle to achieve targeted treatment for specific groups of patients and diseases (1). It is not a new term and concepts similar to PM have surfaced since ancient times (2). As early as the last century, the idea of personalized medicine, a concept similar to PM but more focused on the individual, has come to attention (3). In the 1960s and 1970s, people have already realized the importance of providing the right drug for the right patient (4). The introduction of drug metabolizing enzyme cytochrome P450 (CYP450) and the discovery of human epidermal growth factor receptor 2 (HER2) gene were considered two milestones of PM (5). Later on, the completion of the Human Genome Project (HGP) in 2003 then opened the door to modern PM (6). Nowadays, various omics data, including genomics, epigenomics, transcriptomics, proteomics, metabolomics, and microbiomics, together with data beyond omics, including social, behavior, and environmental factors have been taken into consideration for the field of PM (7). Further details
on PM can be found in the book “Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease” written by the National Research Council of the National Academics in 2011 (8).

In the past one or two decades, countries across the world have successively implemented PM programs (Table 1). Many PM programs are now aimed at generating a large database that contains comprehensive health information of the participants. With the rapid development of big data and artificial intelligence (AI), researchers can then analyze these data to generate biomarkers for predicting, diagnosing, and even possibly treating specific disease subtypes. Therefore, the collection, processing, and interpretation of these data are becoming more and more important. In this article, we summarize current PM programs in different countries as well as some international programs, with a focus on the program at the National University of Singapore (NUS) in Singapore. We discuss the multidisciplinary expertise required, and how our collective efforts can come together to facilitate the vision of realizing PM at NUS. Last but not least, we discuss some of the existing challenges facing PM programs and possible ways of addressing them so as to realize their potential for the future of PM.

OVERVIEW OF GLOBAL PM PROGRAMS

PM has developed rapidly in the last one or two decades. According to Precedence Research, the global PM market is worth over USD $59.5 billion in 2020 and is expected to reach USD $141.33 billion by 2027 (26). Launched in 2015, the Precision Medicine Initiative became the largest longitudinal study in the history of the United States (U.S.), aiming to study diseases by taking the variability in gene, environment, and lifestyle into consideration (1). As the world’s largest developing country, China implemented its PM program named the China’s Precision Medicine Initiative in 2015 (13). European countries have also made a lot of efforts for PM, implementing a series of programs. France implemented the Genomic Medicine France 2025 in 2015, which aims to integrate genomics into the health care system and establish a genomic medicine industry (14). Germany established the Centers for Personalized Medicine in 2019, with the first focus on precision oncology (15). The United Kingdom (U.K.) has also launched the 100,000 Genomes Project in 2013, aiming to perform genome sequencing on people with rare diseases and cancer (18). In Singapore, the National Precision Medicine (NPM) program was launched in 2017, with a 10-year plan aimed at accelerating biomedical research, improving health outcomes, and enhancing opportunities for economic value across sectors (17). With Singapore’s diverse demographics, the NPM program will likely fill in the gaps of inadequate PM data in Asia. We have now summarized a list of national and international PM programs in Table 1.

Besides PM programs initiated by individual countries, some international PM programs have also been established, such as the International HundredK+ Cohorts Consortium (IHCC) (21), the International Consortium for Personalized Medicine (ICPerMed) (22, 23), 1+ Million Genomes Initiative (1+MG) (24), and the Global Alliance for Genomics and Health (GA4GH) (25). These international programs are designed to make up for possible shortcomings of individual programs, bringing together the strengths of different individuals to work together for a common goal.

PM IN NUS, SINGAPORE

As the oldest and most established university in Singapore, the NUS has also launched its own PM program. Led by Prof. Markus Wenk and E Shyong Tai, our PM translational research program (TRP) is comprised of clinician-scientists, population geneticists, genomics and proteomics scientists, bioinformaticians, and cell and molecular biologists coming together to facilitate the necessary pipeline for PM (Figure 1). With this multidisciplinary team, our PM TRP in NUS aims to leverage upon our access to a large and ethnically-diverse population, and use -omics datasets combined with deep mechanistic capabilities to develop targeted therapeutic outcomes for our patients. We want to help stratify populations based on disease mechanisms, identify and validate new therapeutic targets, and then translate these findings to the clinic.

We envision a close collaboration between clinician-scientists, geneticists, data scientists, and basic biologists who can facilitate the passage of clinical insights to disease stratification based on mechanisms and finally to PM right at the bedside (Figure 1). The unique demographic structure of Singapore certainly makes this program even more meaningful as our findings can potentially be applied across Asia, benefitting the Chinese, Malay and Indian ethnicity in our Asia-Pacific region. With the establishment of the National Electronic Health Record (NEHR) at the Singapore national level, we look to tap into the wealth of Asian genetic information, accumulate population-wide omics datasets and perform Asian-specific disease mechanistic studies. Together, our multidisciplinary team within the NUS PM TRP will tackle PM in metabolic disease(s) in the first instance.

DIFFERENT PHASES OF PM AND POTENTIAL CHALLENGES

According to McCarthy and Birney, to truly achieve PM, researchers need to collect data from a wide range of populations, take into account both genetic and non-genetic factors, and stratify/quantify risk levels rather than simply classifying them as low risk or high risk (27). As for its expected results, Prosperi et al. viewed that PM can achieve three goals in a continuous manner: disease diagnosis, disease prediction and prevention, and disease treatment (7). In the actual execution process, PM can be divided into three phases: data collection, data processing, and results interpretation (Figure 1). The quality of these processes will directly determine the final outcomes of PM. In the paragraphs below, some potential challenges regarding these phases will be discussed.

Data Collection

Comprehensive Data Collection

Comprehensive data collection of a targeted population is the first problem all PM programs have to solve. Many current PM programs aim to recruit large numbers of targeted populations to
TABLE 1 | A non-exhaustive list of PM programs in different countries and regional or international PM programs.

| Country | Name of the program | Type of data collected | Number of participants | Year | References |
|---------|---------------------|------------------------|------------------------|------|------------|
| Australia | Australian Genomics | Genomic and clinical data | 5,000 (recruited) | 2016 | (9) |
| Brazil | The Brazilian Initiative on Precision Medicine (BiPMed) | Genomic data | NA | 2015 | (10, 11) |
| Canada | Genome Canada | Genomic and proteomic data | NA | 2000 | (12) |
| China | China’s precision medicine initiative | NA | NA | 2015 | (13) |
| France | Genomic Medicine France 2025 | Genomic data | 10,000 (planned) | 2015 | (14) |
| Germany | The Centers for Personalized Medicine | NA | NA | 2019 | (15) |
| Japan | Cancer Genome Screening Project for Individualized Medicine in Japan | Genomic, transcriptomic, and proteomic data | 20,000 (recruited) | 2015 | (16) |
| Singapore | Singapore’s national precision medicine (NPM) program | Genomic, clinical, and lifestyle data | Around 1,000,000 (planned) | 2017 | (17) |
| U.K. | 100,000 Genomes Project | Genomic data | 85,000 (recruited) | 2013 | (18) |
| U.S. | Precision Medicine Initiative (All of Us) | Participant-provided information, Electronic Health Records, physical measurements, and biospecimens | 1,000,000 or more (planned) | 2015 | (1, 19) |
| Denmark, Iceland, Estonia, Norway, Finland, Sweden | Nordic Society of Human Genetics and Precision Medicine | NA | NA | 2018 | (20) |
| International | International HundredK+ Cohorts Consortium (I-HCC) | NA | 100,000 or more (planned) | 2018 | (21) |
| International (mainly European countries) | The International Consortium for Personalized Medicine (ICPerMed) | Molecular profiling, medical imaging, and lifestyle data | NA | 2016 | (22, 23) |
| European Union countries, U.K., Norway | 1+ Million Genomes Initiative (1+MG) | Genomic data | 1,000,000 genomes (planned) | 2018 | (24) |
| International | The Global Alliance for Genomics and Health (GA4GH) | Genomic and phenotypic data | NA | 2013 | (25) |

NA indicates that the data could not be found.

build a comprehensive database. For example, Singapore’s NPM program recruited 10,000 healthy people in its first phase and plans to recruit 100,000 healthy individuals and 50,000 patients with specific diseases in its second phase. This program will collect genomic data and other types of health data that can synergistically provide a comprehensive picture of a person’s health status. Many other PM programs also collect a lot of data about a person’s health. Therefore, big data will certainly form the core of PM. The creation of biological databases and biobanks that provide health information can undoubtedly help this process. With large, comprehensive databases, researchers can share the data with each other and obtain the information that they need more readily.

Problems During Data Collection and Possible Solutions

While the establishment of these databases will undoubtedly promote the development of PM, the data collection process inevitably raises some concerns. One of the major concerns is the anonymity or privacy of the participants. Participants or patients with a specific disease voluntarily provide data but the data must be kept anonymous during the study. De-identification is the process that removes the information that is directly or indirectly related to the participant (28). This process is essential to protect the privacy of the participants. However, achieving complete data anonymity is technically difficult, and is not desirable for some PM programs that involve clinical care (28). Therefore, it is understandable that society will have concerns and distrust over medical data security and how it can be properly guarded. This will inevitably retard the data collection process, and thus impede the development of PM to some extent. The continued development of AI technologies may eventually provide a solution to the security and privacy of the data. Briguglio et al. described a machine learning (ML) method to ensure patient privacy via encryption (29). Besides, Warnat-Herresthal et al. developed swarm learning method that helps data integration on the premise of confidentiality (30). By reducing direct human involvement, AI may provide some level of protection on data security and privacy.
In a type of targeted clinical study named recall-by-genotype (RbG) study, participants with defined genetic variations are specifically recruited \( (31) \). While participant anonymity and privacy become harder to protect due to the targeted recruitment of a small number of individuals, this study design is more cost-effective than other approaches as the research can be conducted in-depth on a small number of participants \( (31) \). Importantly, the RbG study can facilitate the elucidation of causal relationship between genetic variation and human physiology. Further biochemical and human cellular studies performed on these participants can then provide more definitive data that can eventually aid in the decision-making matrix for the implementation of PM.

**Appropriate Choice and Interpretation of the Model System**

With the availability of sequencing-based technologies and -omics methods, data collection, processing, and interpretation for genomics, epigenomics, transcriptomics, proteomics, metabolomics, and microbiomics datasets are seemingly straightforward. However, the major difficulty is likely to be the choice and availability of the correct human cell type at the correct developmental state for -omics analyses. For any given gene variant of interest, the cell type in which it is studied will result in a different interpretation as the transcriptional network and/or signaling pathways affected can be cell-type- and cell state-specific. Gene targets may differ in different cellular contexts. The use of readily available human primary cells such as blood, skin, fat, or muscle cells vs. human induced pluripotent stem cell (hiPSC)-derived cell types such as brain, liver, or pancreas cells will also need to be determined carefully.

Introduction of gene correction of variants in these human cell types for -omics data collection is also a current possibility. Last but not least, data collection from properly-determined cellular functional assays will also be critical for ascertaining genotype-phenotype causality.

In addition to finding population-specific targets using various omics technologies, another important aspect of PM is to perform population/genotype-based drug screening. Animal models and immortalized cell lines are two commonly used methods for drug screening \( (32) \). However, animal models often have interspecies differences \( (33) \), and many successful experiments in animal models do not translate well into clinical trials \( (32) \). Immortalized cell lines may also exhibit some differences compared to primary human cells \( (32) \). In recent years, the hiPSC-derived organoid model has become a popular model for studying the effects of human gene variants on cellular development and function \( (34–36) \). These cells can be used for population/genotype-based drug screening.

Besides the type of human cell and their cell state, the scale at which data needs to be collected for PM efforts will also need to be immense. Following which, there is also a need for a standardized process in which data is collected so that they can be processed in a similar manner for consistent and reproducible interpretation. In this regard, inter-laboratory comparison trials (or ring trials) will also be required to demonstrate the robustness of data collection processes that will ultimately lead to consistent and reproducible data. The use of pre-determined targeted gene/molecular panels instead of unrestricted-omics data collection may also be easier to synchronize data processing efforts.
Data Processing
Data that has been collected will need to be processed and analyzed in detail by researchers to stratify populations into subgroups with different risk levels, so that novel biomarkers can be discovered and used in disease prediction, diagnosis, and treatment. Currently, there is still a need for detailed characterization of the roles of many human genes/molecules/proteins, development of a comprehensive human gene regulatory map, and catalog of cellular programs. This will be the basis in which the effects of gene variants can be compared against. Functional assays to determine the roles of many human genes in various cell types remain to be established. Therefore, many discoveries are still not well-translated into clinical strategies. Besides, the current complex biological systems without sufficient mechanistic understanding make it difficult to predict individual disease conditions and outcomes properly (37).

Although the development of AI and novel algorithms has greatly helped in data processing, insufficiently standardized data processing criteria may still render results to be irreproducible or unreliable. This is particularly evident in some omics datasets. On one hand, researchers would want to include more variables to improve the accuracy of their prediction (37). But on the other hand, the large number of variables itself greatly increases the difficulty of prediction (37). Striking a fine balance between these two parameters will be crucial in managing successful PM outcomes.

Results Interpretation
Following data collection and processing, correct and appropriate data interpretation is likely the hardest and the most important part in order to realize its clinical value for PM. Omics data is understandably an important part of PM and researchers will typically focus on capturing invariant genomics data at the population level before expanding the scope to other dynamic omics datasets such as proteomics and metabolomics.

The discovery and interpretation of omics data currently present a major challenge for PM. Firstly, there is a large number of unknown regions in the human genome that impedes the decoding of the genome, thus hindering the development of PM. Whole genome sequencing (WGS) will readily facilitate deciphering of the coding region of the human genome but it only accounts for about 2% of the whole genome (38). The remaining 98% of the genome is thought to be associated with non-coding RNAs, regulatory sequences, and other sequences that might play a role and contribute to human disease. However, the function of most of these sequences and genomic interactions remain unclear to date. This is indeed a huge challenge for the realization of the utility of PM. Therefore, there is a need for more efforts focused on deep mechanistic studies at the cell and molecular level, to complement all the high throughput data collection. One current problem is the existence of variants of uncertain significance (VUS). VUS refers to the genetic variation that has been identified but without a clear function. It is currently almost impossible to track and interpret all the VUSs in patients (38). Hence, the presence of VUSs makes it even harder to accurately analyze the detailed mechanisms of some human diseases. For example, breast cancer 1 (BRCA1) and BRAC2 are two widely studied genes. While lots of studies have been done on them, they still produce VUSs regularly (39). Much more human biology remains to be researched upon. In recent years, the growing interest in RNA biology and the use of bulk and single cell transcriptomics analyses may partly help to solve this problem.

The next concern facing PM is the appropriate explanation of these gene variants. With the rapid development of omics technologies, we can get the correct and precise localization of these gene variants. However, in many instances, their meaning in a particular population or group of individuals remain totally unclear. Genes are related and integrated functionally. Therefore, in different biological contexts, the effect of the same gene mutation might be different (40). In the same vein, the meaning of proteomic or metabolomic signatures in a stratified population will also need to be understood. These uncertainties increase the difficulties of interpreting the effects of gene variants. In order to do so, these gene variants and molecular differences will need to be studied in relevant animal/cell models in detail so as to interpret the meaning and apply the findings appropriately for stratified medicine. Thus far, some omics data have been successfully applied in PM. For instance, breast cancer is a highly heterogeneous disease where different disease subtypes have different pathogenesis and will need different treatment methods (41). Currently, breast cancer has been successfully divided into different subtypes, and its molecular mechanism(s) have been studied to a certain extent (41). This will help the targeted treatment for different patients. Familial hypercholesterolemia (FH) is another successful example. FH is a genetic cardiovascular disease that can increase the risk of having premature atherosclerotic cardiovascular disease if not treated properly (42). To address FH, Identification Methods, Patient Activation, and Cascade Testing for FH (IMPACT-FH) Study, a multi-disciplinary study, was established to help to identify individuals with high risk of having FH (43). In addition, the use of omics data to identify biomarkers to accurately predict disease occurrence and progression is also an important aspect of PM. Li et al. successfully identified oligoadenylate synthetases-like as a gene biomarker in differentiating non-influenza- and influenza-based acute respiratory infection using bioinformatics tools (44). Therefore, biomarkers identified by omics technologies might provide a good way to predict diseases at the population level. With the continuous development of various technologies, strategies, and in-depth mechanistic studies into unique gene variants and/or molecular differences between population groups, we can expect more successful applications for PM in the near future.

Upon successfully interpreting the meaning of gene variants and molecules linked to a particular disease, the adoption strategy is also critical for PM. First, the data collected, processed (e.g., data transformation), and interpreted needs to be packaged (e.g., presented with appropriate visualization) in a meaningful way that clinicians can understand. These test results must remain compliant with a myriad of regulatory constraints, integrating across data, lab, product, and business practice. Thereafter,
clinicians need to be able to make the test accessible to patients and interpret the test for them. The test results need to be customizable and adapted to the needs of patients as patients may have difficulties understanding basic medical information and may not be ready to receive unexpected results (45). Appropriate decision support also needs to be in place during this stakeholder engagement. Clinically, Qian et al. developed a multidisciplinary therapy strategy of precision medicine (MDTS-PM) to apply PM, covering the whole range of services from diagnosis to treatment (42). In the field of tumor biology, Qian et al. opined that patients who have reliable gene test results, complex refractory tumors and drug resistance, are suitable for PM, and appropriate multidisciplinary therapy (MDT) strategy can have maximum benefits to those patients and clinicians (46).

DISCUSSION

The implementation of PM programs has indeed attracted extensive attention since its conception. In general, PM can be regarded as the use of technical means to analyze big data of healthy populations and patients with specific disease(s) to achieve precise prediction, diagnosis, and treatment of specific subgroups of patients. Unlike personalized medicine, which pays more attention to individuals, PM mainly focuses on the stratification of patients with seemingly similar disease, e.g., diabetes, into subpopulations of patients based on disease mechanism to develop targeted therapeutic strategies (3). In recent years, with the development of big data and AI, the establishment of PM programs in various countries has also developed rapidly. This article has summarized the PM programs in different countries, with a focus on the PM TRP of NUS. Drawing on the strengths of clinicians, omics scientists, bioinformaticians, and biologists, combined with Singapore’s NUS. Drawing on the strengths of clinicians, omics scientists, bioinformaticians, and biologists, combined with Singapore's multiracial population, the NUS PM TRP is expected to fill a gap in Asia's PM database.

From sample collection, data processing, and results interpretation point of view, this article has also raised some concerns that need to be actively addressed. PM involves a large amount of sample collection. Thus, it is necessary to establish a comprehensive set of rules and laws to protect the rights and interests of the participants. A complete and standardized sample collection, data processing, and results interpretation system also needs to be established to effectively promote the development of PM. Last but not least, a lot more effort needs to go into the mechanistic interpretation of all the data collected, including the meaning of variants and molecules unique to specific populations so that PM outputs such as predictive polygenic risk score (PRS) for disease(s) and targeted clinical interventions can be implemented in time to come.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article. Further inquiries can be directed to the corresponding author.

AUTHOR CONTRIBUTIONS

AT: conceptualization and supervision. DK: writing original draft. DK, HY, XS, KW, ET, MW, and AT: review and editing. All authors contributed to the article and approved the submitted version.

FUNDING

DK was supported by the NUS Research Scholarship. AT was supported by IMCB, A*STAR, Lee Foundation Grant SHTX/LFG/002/2018, FY2019 SingHealth Duke-NUS Surgery Academic Clinical Programme Research Support Programme Grant, Precision Medicine and Personalized Therapeutics Joint Research Grant 2019, Industry Alignment Fund – Industry Collaboration Project (IAF-ICP) I1901E0049, the 2nd A*STAR-AMED Joint Grant Call 192B9002, NUHSRO/2021/035/NUSMed/04/NUS-IMCB Joint Lab/LOA, Paris-NUS 2021-06-R/UP-NUS (ANR-18-IDEX-0001), OFIRG21jun-0097, CSASI21jun-0006 and MTCIRG21-0071.

REFERENCES

1. Sankar PL, Parker LS. The precision medicine initiative’s all of US research program: an agenda for research on its ethical, legal, and social issues. Genet Med. (2017) 19:743–50. doi: 10.1038/gim.2017.183
2. Konstantinidou MK, Karaglani M, Panagopoulou M, Fiska A, Chatzaki E. Are the origins of precision medicine found in the corpus hippocraticum? Mol Diagn Ther. (2017) 21:601–6. doi: 10.1007/s40291-017-0291-y
3. Strianese O, Rizzo F, Ciccarelli M, Galasso G, D’Agostino Y, Salvati A, et al. Precision and personalized medicine: how genomic approach improves the management of cardiovascular and neurodegenerative disease. Genes. (2020) 11:747. doi: 10.3390/genes11070747
4. Jorgensen JT. Twenty years with personalized medicine: past, present, and future of individualized pharmacotherapy. Oncologist. (2019) 24:e432–e40. doi: 10.1634/theoncologist.2019-0054
5. Visvikis-Siest S, Theodoridou D, Kontoe MS, Kumar S, Marschler M. Milestones in personalized medicine: from the ancient time to nowadays—the provocation of COVID-19. Front Genet. (2020) 11:569175. doi: 10.3389/fgene.2020.569175
6. Furlani B, Kouter K, Rozman D, Videtic Paska A. Sequencing of nucleic acids: from the first human genome to next generation sequencing in [COVID-19] pandemic. Acta Chim Slov. (2021) 68:268–78. doi: 10.17344/acs2.2021.6691
7. Prosperi M, Min JS, Bian J, Modave F. Big data hurdles in precision medicine and precision public health. BMC Med Inform Decis Mak. (2018) 18:139. doi: 10.1186/s12911-018-0719-2
8. Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease. The National Academies Collection: Reports funded by National Institutes of Health. Washington, DC: National Academies Press (US) (2011).
9. Australian Genomics. Available online at: https://www.australiangenomics.org.au/ (accessed: December 26, 2021).
10. BIPMed Brazilian Initiative on Precision Medicine. Available online at: http://www.bipmed.org (accessed: December 26, 2021)
11. Rocha CS, Secolin R, Rodrigues MR, Carvalho, BS, Lopes-Cendes I. The Brazilian Initiative on Precision Medicine (BIPMed): fostering genomic
data-sharing of underrepresented populations. NPJ Genom Med. (2020) 5:42. doi: 10.1038/s41525-020-00149-6

12. Genome Canada. Available online at: https://www.genomecanada.ca/en/programs/precision-health-strategy-canada-think-big-start-small-learn-fast (accessed: December 26, 2021).

13. Liu J, Hui RT, Song L. Precision cardiovascular medicine in China. J Geriatr Cardiol. (2020) 17:638–41. doi: 10.11909/j.issn.1671-5411.2020.10.005

14. Lethimonnier F, Levy Y. Genomic medicine France 2025. Ann Oncol. (2018) 29:783–4. doi: 10.1093/annonc/mdy027

15. Stenzinger A, Edsjö A, Ploeger C, Friedman M, Fröhling S, Wirta V, et al. Trailblazing precision medicine in Europe: a joint view by Genomic Medicine Sweden and the Centers for Personalized Medicine, ZPM, in Germany. Semin Cancer Biol. (2021) 51044-579X(21)00156-5. doi: 10.1016/j.semcancer.2021.05.026

16. National Cancer Center Japan (2021). Available online at: https://www.ncc.go.jp/en/information/press_release/20210630/index.html (accessed: December 26, 2021).

17. PRECISE Precision Health Research Singapore. Available online at: https://www.nmp.sg/ (accessed: December 26, 2021).

18. Genomics England. Available online at: https://www.genomicsengland.co.uk/ (accessed: December 26, 2021).

19. All of Us Research Program (2018). Available online at: https://allofus.nih.gov/sites/default/files/all_of_us_protocol_v1_summary.pdf (accessed: December 26, 2021).

20. Nordic Society of Human Genetics and Precision Medicine. Available online at: https://www.nhsb-gm.org/ (accessed: December 26, 2021).

21. International HundredK+ Cohorts Consortium. Available online at: https://ihcglobal.org/ (accessed: December 26, 2021).

22. ICPerMed International Consortium. Available online at: https://icpermed.eu/index.php (accessed: December 26, 2021).

23. Venne J, Busshoff U, Poschadel S, Menschel R, Evangelatos N, Vysyaraju K, et al. International consortium for personalized medicine: an international survey about the future of personalized medicine. Per. Med. (2020) 17:89–100. doi: 10.2217/pme-2019-0093

24. European ‘1+ Million Genomes’ Initiative. Available online at: https://digital-strategy.ec.europa.eu/en/policies/1-million-genomes (accessed: December 26, 2021).

25. Global Alliance for Genomics and Health. Available online at: https://www.ga4gh.org/ (accessed: December 26, 2021).

26. Precedence Research. Precision Medicine Market (By Technology: Bioinformatics, Big Data Analytics, Drug Discovery, Gene Sequencing, Companion Diagnostics, and Others; By Application: CNS, Immunology, Oncology, Respiratory, and Others; By End-use: Diagnostic Companies, Pharmaceutical Companies, Healthcare IT companies, and Others) - Global Market Size, Trends Analysis, Segment Forecasts, Regional Outlook 2020–2027. Available online at: https://www.precedenceresearch.com/precision-medicine-market (accessed: December 26, 2021).

27. McCarthy M, Birney E. Personalized profiles for disease risk must capture all facets of health. Nature. (2021) 597:157–7. doi: 10.1038/d41586-021-02401-0

28. Lysaght T, Ballantyne A, Xafis V, Ong S, Schaefer GO, Ling JMT, et al. Who is watching the watchdog?1: ethical perspectives of sharing health-related data for precision medicine in Singapore. BMC Med Ethics. (2020) 21:118. doi: 10.1186/s12910-020-00128-1

29. Brugiglio W, Moghadam P, Yousef WA, Traoré I, Mamun M. Machine learning in precision medicine to preserve privacy via encryption. Pattern Recognit Lett. (2021) 151:148–54. doi: 10.1016/j.patrec.2021.07.004

30. Warnat-Herresthal S, Schultz H, Shastry KL, Mananmoham S, Mukherjee S, Garg V, et al. Swarm Learning for decentralized and confidential clinical machine learning. Nature. (2021) 594:265–70. doi: 10.1038/d41586-021-03583-3

31. Minion JT, Butcher F, Timpson N, Murtagh MJ. The ethics conundrum in Recall by Genotype (RBG) research: perspectives from birth cohort participants. PLoS ONE. (2018) 13:e0202502. doi: 10.1371/journal.pone.0202502

32. Xu XH, Zhong Z. Disease modeling and drug screening for neurological diseases using human induced pluripotent stem cells. Acta Pharmacol Sin. (2013) 34:755–64. doi: 10.1038/aps.2013.63

33. Elliott MS, Barbar L, Tesar P. Drug screening for human genetic diseases using iPSC models. Hum Mol Genet. (2018) 27:899–899. doi: 10.1093/hmg/ddy186

34. Amiruddin NS, Low BSJ, Lee KO, Tai ES, Teo AKK. New insights into human beta cell biology using human pluripotent stem cells. Semin Cell Dev Biol. (2020) 103:31–40. doi: 10.1016/j.semcdb.2019.11.004

35. Yang T, Wagers AJ, Kulkarni RN. New opportunities: harnessing induced pluripotency for discovery in diabetes and metabolism. Cell Metab. (2013) 18:775–91. doi: 10.1016/j.cmet.2013.08.010

36. Yang T, Gupta MK, Doria A, Kulkarni RN. Dissecting diabetes/metabolic disease mechanisms using pluripotent stem cells and genome editing tools. Mol Metab. (2015) 4:593–604. doi: 10.1016/j.molmet.2015.06.006

37. Vogt H, Green S, Ekstrom CT, Brodersen J. How precision medicine and screening with big data could increase overdiagnosis. BMJ. (2019) 366:135270. doi: 10.1136/bmj.135270

38. Pyeritz RE. Uncertainty in genomics impacts precision medicine. Trends Genet. (2021) 37:711–6. doi: 10.1016/j.tig.2020.10.010

39. Eccles BK, Copson E, Maishman T, Abraham JE, Eccles DM. Understanding of BRCA VUS genetic results by breast cancer specialists. BMC Cancer. (2015) 15:936. doi: 10.1186/1475-2840-15-934-1

40. Singh RS, Gupta BP. Genes and genomes and unnecessary complexity in precision medicine. NPJ Genom Med. (2020) 5:21. doi: 10.1038/s41525-020-0128-1

41. Sachdev JC, Sandoval AC, Jahanzeb M. Update on precision medicine in breast cancer. Cancer Treat Rev. (2019) 78:45–80. doi: 10.1016/j.ctrv.2019.07.004

42. Qian M, Li Q, Zhang M, Xu X, Shen Q, Chen H, et al. Multidisciplinary therapy strategy of precision medicine in clinical practice. Clin Transl Med. (2020) 10:116–24. doi: 10.1002/ctm2.15

43. Campbell-Salome G, Jones LK, Masnick MF, Walton NA, Ahmed CD, Buchanan AH, et al. Developing and optimizing innovative tools to address familial hypercholesterolemia underdiagnosis: identification methods, patient activation, and cascade testing for familial hypercholesterolemia. Crc Genom Precis Med. (2021) 14:e003120. doi: 10.1161/CIRCGEN.120.003120

44. Li Y, Liu H, Xu Q, Wu R, Zhang Y, Li N, et al. OASL as a Diagnostic marker for influenza infection revealed by integrative bioinformatics analysis with XGBoost. Front Biosci Biol Technol. (2020) 8:729. doi: 10.3389/fbioe.2020.00729

45. Budin-Liosne I, Harris JR. Patient and interest organisations’ views on personalized medicine: a qualitative study. BMC Med Ethics. (2016) 17:288. doi: 10.1186/s12910-016-0117-7

46. Qian M, Chen H, Wu D, Qiao T, Shen H, Cheng Y. The application of multidisciplinary therapy strategy of precision medicine in tumour diagnosis and treatment. Clin Transl Disc. (2021) 1:e10. doi: 10.1002/ctd2.10

Conflict of Interest: AT is a co-founder of BetaLife Pte Ltd, but he is not employed by BetaLife Pte Ltd.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Kong, Yu, Sim, White, Tai, Wenk and Teo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.